Clinical Trials Logo

Asymptomatic Hyperuricemia clinical trials

View clinical trials related to Asymptomatic Hyperuricemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05302388 Completed - Clinical trials for Asymptomatic Hyperuricemia

A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

Start date: April 11, 2022
Phase: Phase 1
Study type: Interventional

The main purpose To evaluate the safety and tolerability of pegloticase in subjects with asymptomatic hyperuricemia by single intravenous infusion at different doses, and to provide a basis for multiple doses of Pegloticase in subjects with asymptomatic hyperuricemia. A secondary purpose To evaluate the pharmacokinetics, pharmacodynamics and immunogenicity of Pegloticase with single-pass intravenous drip in subjects with asymptomatic hyperuricemia. Exploratory purpose Plasma uricase activity (pUox) analysis of pegloticase with single-pass intravenous drip in subjects with asymptomatic hyperuricemia.

NCT ID: NCT03316131 Completed - Clinical trials for Asymptomatic Hyperuricemia

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Start date: October 25, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit